{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T10:32:03Z","timestamp":1777545123027,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001646","name":"Robert Bosch Stiftung","doi-asserted-by":"publisher","award":["COR-101"],"award-info":[{"award-number":["COR-101"]}],"id":[{"id":"10.13039\/501100001646","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Forschung, Technologie und Raumfahrt","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["EXC 2180 \\u2013 390900677"],"award-info":[{"award-number":["EXC 2180 \\u2013 390900677"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.clinthera.2026.01.004","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T05:03:50Z","timestamp":1770440630000},"page":"232-239","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phase I Study Evaluating a Monoclonal Fc-Silenced SARS-CoV-2 Antibody in Patients With Moderate-to-Severe COVID-19"],"prefix":"10.1016","volume":"48","author":[{"given":"Maddalena","family":"Marconato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Hackenbruch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"J\u00e4ger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siri","family":"G\u00f6pel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetiana","family":"\u041airieieva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anatoliy","family":"Gavrylov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald","family":"Fricke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Hust","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"D\u00fcbel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christiane","family":"Dings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thorsten","family":"Lehr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mandy","family":"Cuevas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Bitzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Constantin","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Schwab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hubert","family":"Wirtz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jochen","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Bitter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9","family":"Frenzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Ann","family":"Dhaen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gundram","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliane S.","family":"Walz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helmut R.","family":"Salih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonas S.","family":"Heitmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2026.01.004_bib0001","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41579-023-00878-2","article-title":"The evolution of SARS-CoV-2","volume":"21","author":"Markov","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.clinthera.2026.01.004_bib0002","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/s41586-021-03777-9","article-title":"Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization","volume":"596","author":"Planas","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2026.01.004_bib0003","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41591-021-01294-w","article-title":"Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies","volume":"27","author":"Chen","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.clinthera.2026.01.004_bib0004","doi-asserted-by":"crossref","first-page":"9763","DOI":"10.3390\/ijms23179763","article-title":"Evolution of anti-SARS-CoV-2 therapeutic antibodies","volume":"23","author":"Almagro","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clinthera.2026.01.004_bib0005","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2026.01.004_bib0006","unstructured":"FDA. Bamlanivimab: emergency use authorization. U.S. Food and Drug Administration. Accessed June 01, 2025. https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibody-treatment-covid-19."},{"key":"10.1016\/j.clinthera.2026.01.004_bib0007","unstructured":"FDA. Casirivimab and imdevimab: emergency use authorization. U.S. Food and Drug Administration. Accessed June 01, 2025 https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-november-23-2020."},{"key":"10.1016\/j.clinthera.2026.01.004_bib0008","unstructured":"FDA. Sotrovimab: emergency use authorization. U.S. Food and Drug Administration. Accessed June 01, 2025 https:\/\/www.fda.gov\/media\/150130\/download."},{"key":"10.1016\/j.clinthera.2026.01.004_bib0009","unstructured":"FDA. Tixagevimab and cilgavimab: emergency use authorization. U.S. Food and Drug Administration. Accessed June 01, 2025 https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-announces-evusheld-not-currently-authorized-emergency-use-us."},{"key":"10.1016\/j.clinthera.2026.01.004_bib0010","unstructured":"FDA. Bamlanivimab: UPDATE emergency use authorization. U.S. Food and Drug Administration. Accessed June 01, 2025 https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-monoclonal-antibody-bamlanivimab#:~:text=Today%2C%20the%20U.S.%20Food%20and,adults%20and%20certain%20pediatric%20patients."},{"key":"10.1016\/j.clinthera.2026.01.004_bib0011","doi-asserted-by":"crossref","first-page":"eabg3055","DOI":"10.1126\/science.abg3055","article-title":"Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England","volume":"372","author":"Davies","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2026.01.004_bib0012","first-page":"8012","article-title":"Omicron SARS-CoV-2 new variant: global prevalence and biological and clinical characteristics","volume":"25","author":"Meo","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.clinthera.2026.01.004_bib0013","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41586-021-04388-0","article-title":"Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2","volume":"602","author":"Liu","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2026.01.004_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109433","article-title":"A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations","volume":"36","author":"Bertoglio","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.clinthera.2026.01.004_bib0015","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/imr.12367","article-title":"Fc receptors in antibody-dependent enhancement of viral infections","volume":"268","author":"Taylor","year":"2015","journal-title":"Immunol Rev"},{"key":"10.1016\/j.clinthera.2026.01.004_bib0016","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10928-007-9060-6","article-title":"Derivation of various NONMEM estimation methods","volume":"34","author":"Wang","year":"2007","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.clinthera.2026.01.004_bib0017","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1038\/psp.2013.71","article-title":"Basic concepts in population modeling, simulation, and model-based drug development: part 3-introduction to pharmacodynamic modeling methods","volume":"3","author":"Upton","year":"2014","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.clinthera.2026.01.004_bib0018","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/sj.clpt.6100241","article-title":"Diagnosing model diagnostics","volume":"82","author":"Karlsson","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2026.01.004_bib0019","doi-asserted-by":"crossref","first-page":"eabc7112","DOI":"10.1126\/sciadv.abc7112","article-title":"Potency and timing of antiviral therapy as determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory response","volume":"6","author":"Goyal","year":"2020","journal-title":"Sci Adv"},{"key":"10.1016\/j.clinthera.2026.01.004_bib0020","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.3390\/pharmaceutics14102059","article-title":"Pharmacometric modeling of the impact of azelastine nasal spray on SARS-CoV-2 viral load and related symptoms in COVID-19 patients","volume":"14","author":"Dings","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.clinthera.2026.01.004_bib0021","doi-asserted-by":"crossref","first-page":"4545","DOI":"10.1038\/s41467-023-40204-1","article-title":"Monoclonal antibody levels and protection from COVID-19","volume":"14","author":"Stadler","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.clinthera.2026.01.004_bib0022","doi-asserted-by":"crossref","DOI":"10.1172\/JCI158190","article-title":"Antibodies from convalescent plasma promote SARS-CoV-2 clearance in individuals with and without endogenous antibody response","volume":"132","author":"Marconato","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2026.01.004_bib0023","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41573-023-00672-y","article-title":"Therapeutic strategies for COVID-19: progress and lessons learned","volume":"22","author":"Li","year":"2023","journal-title":"Nat Rev Drug Discov"},{"issue":"suppl 2","key":"10.1016\/j.clinthera.2026.01.004_bib0024","first-page":"31","article-title":"SARS CoV subunit vaccine: antibody-mediated neutralisation and enhancement","volume":"18","author":"Jaume","year":"2012","journal-title":"Hong Kong Med J"},{"key":"10.1016\/j.clinthera.2026.01.004_bib0025","doi-asserted-by":"crossref","first-page":"e02015","DOI":"10.1128\/JVI.02015-19","article-title":"Molecular mechanism for antibody-dependent enhancement of coronavirus entry","volume":"94","author":"Wan","year":"2020","journal-title":"J Virol"},{"key":"10.1016\/j.clinthera.2026.01.004_bib0026","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.123158","article-title":"Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection","volume":"4","author":"Liu","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.clinthera.2026.01.004_bib0027","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.3390\/v15112153","article-title":"Evaluation of the neutralizing antibody STE90-C11 against SARS-CoV-2 delta infection and its recognition of other variants of concerns","volume":"15","author":"Abassi","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.clinthera.2026.01.004_bib0028","unstructured":"FDA. FDA updates Sotrovimab emergency use authorization. U.S. Food and Drug Administration.Accessed June 05, 2025 https:\/\/www.fda.gov\/news-events\/press-ann"},{"key":"10.1016\/j.clinthera.2026.01.004_bib0029","unstructured":"FDA. FDA announces Evusheld is not currently authorized for emergency use in the U.S. U.S. Food and Drug Administration. Accessed June 05, 2025. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-announces-evusheld-not-currently-authorized-emergency-use-us."},{"key":"10.1016\/j.clinthera.2026.01.004_bib0030","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ijid.2020.09.015","article-title":"Antibody-dependent enhancement of coronavirus","volume":"100","author":"Wen","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.clinthera.2026.01.004_bib0031","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-020-2571-7","article-title":"Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike","volume":"584","author":"Liu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.clinthera.2026.01.004_bib0032","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41586-020-2538-8","article-title":"A perspective on potential antibody-dependent enhancement of SARS-CoV-2","volume":"584","author":"Arvin","year":"2020","journal-title":"Nature"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929182600007X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929182600007X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T17:32:27Z","timestamp":1777397547000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014929182600007X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S014929182600007X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.01.004","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I Study Evaluating a Monoclonal Fc-Silenced SARS-CoV-2 Antibody in Patients With Moderate-to-Severe COVID-19","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}